Otsuka Holdings Co., Ltd. (OTSKF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 10:48AM EDT. Market open.
| Previous close | 40.81 |
| Open | 40.81 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 40.81 - 40.81 |
| 52-week range | 29.57 - 41.59 |
| Volume | |
| Avg. volume | 93 |
| Market cap | 22.223B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 28.14 |
| EPS (TTM) | 1.45 |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (1.95%) |
| Ex-dividend date | 27 Jun 2024 |
| 1y target est | N/A |
ZacksIonis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
Business WireRecor Medical Announces U.S. Launch and First Commercial Cases of Paradise Ultrasound Renal Denervation Therapy
PALO ALTO, Calif., November 10, 2023--Recor Medical, Inc. announces the first commercial uses of Recor’s Paradise™ Ultrasound Renal Denervation system for the treatment of hypertension.
Business WireRecor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
PALO ALTO, Calif., November 08, 2023--Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
© 2024 Yahoo. All rights reserved.